CA2272719A1 - Amides inhibant la secretion d'apo b et/ou la proteine mtp - Google Patents

Amides inhibant la secretion d'apo b et/ou la proteine mtp Download PDF

Info

Publication number: CA2272719A1
Authority: CA; Canada
Prior art keywords: inhibitors; compounds; hmg; useful; apo
Prior art date: 1996-11-27
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

CA002272719A

Other languages

English (en)

Other versions

CA2272719C (fr

Inventor

George Chang

George Joseph Quallich

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Pfizer Ltd Great Britain

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-11-27

Filing date

1997-11-03

Publication date

1998-06-04

1997-11-03 Application filed by Individual filed Critical Individual

1998-06-04 Publication of CA2272719A1 publication Critical patent/CA2272719A1/fr

2002-10-01 Application granted granted Critical

2002-10-01 Publication of CA2272719C publication Critical patent/CA2272719C/fr

2017-11-03 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Diabetes (AREA)
Veterinary Medicine (AREA)
Hematology (AREA)
Obesity (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Child & Adolescent Psychology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Plural Heterocyclic Compounds (AREA)
Indole Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Other In-Based Heterocyclic Compounds (AREA)

CA002272719A 1996-11-27 1997-11-03 Amides inhibant la secretion d'apo b et/ou la proteine mtp Expired - Fee Related CA2272719C (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US3230796P	1996-11-27	1996-11-27
US60/032,307		1996-11-27
PCT/IB1997/001368 WO1998023593A1 (fr)	1996-11-27	1997-11-03	AMIDES INHIBANT LA SECRETION D'Apo B ET/OU LA PROTEINE MTP

Publications (2)

Publication Number	Publication Date
CA2272719A1 true CA2272719A1 (fr)	1998-06-04
CA2272719C CA2272719C (fr)	2002-10-01

Family

ID=21864233

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002272719A Expired - Fee Related CA2272719C (fr)	1996-11-27	1997-11-03	Amides inhibant la secretion d'apo b et/ou la proteine mtp

Country Status (34)

Country	Link
US (1)	US6121283A (fr)
EP (1)	EP0944602A1 (fr)
JP (1)	JP3270764B2 (fr)
KR (1)	KR100334567B1 (fr)
CN (2)	CN1238764A (fr)
AP (1)	AP804A (fr)
AR (1)	AR010309A1 (fr)
AU (1)	AU716151B2 (fr)
BG (2)	BG103434A (fr)
BR (1)	BR9714364A (fr)
CA (1)	CA2272719C (fr)
CZ (1)	CZ292160B6 (fr)
DZ (1)	DZ2358A1 (fr)
EA (1)	EA001539B1 (fr)
GT (1)	GT199700122A (fr)
HN (1)	HN1997000144A (fr)
HR (1)	HRP970642A2 (fr)
ID (1)	ID18995A (fr)
IL (1)	IL129744A0 (fr)
IS (1)	IS5040A (fr)
MA (1)	MA26451A1 (fr)
NO (1)	NO312760B1 (fr)
NZ (1)	NZ335162A (fr)
OA (1)	OA11050A (fr)
PA (1)	PA8441601A1 (fr)
PE (1)	PE17199A1 (fr)
SK (1)	SK65499A3 (fr)
TN (1)	TNSN97193A1 (fr)
TR (1)	TR199901180T2 (fr)
TW (1)	TW502023B (fr)
UY (1)	UY24789A1 (fr)
WO (1)	WO1998023593A1 (fr)
YU (1)	YU23499A (fr)
ZA (1)	ZA9710641B (fr)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6262277B1 (en)	1994-09-13	2001-07-17	G.D. Searle And Company	Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6642268B2 (en)	1994-09-13	2003-11-04	G.D. Searle & Co.	Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
DK0832069T3 (da) *	1995-06-07	2003-04-22	Pfizer	Biphenyl-2-carboxylsyre-tetrahydroisoquinolin-6-ylamidderivater, deres fremstilling og deres anvendelse som inhibitorer af sekretion af mikrosomalt triglyceridoverførselsprotein og/eller apolipoprotein B (Apo B)
GB9708805D0 (en)	1997-05-01	1997-06-25	Smithkline Beecham Plc	Compounds
US5968950A (en) *	1997-06-23	1999-10-19	Pfizer Inc	Apo B-secretion/MTP inhibitor hydrochloride salt
GB9810876D0 (en)	1998-05-20	1998-07-22	Smithkline Beecham Plc	Compounds
US6288234B1 (en)	1998-06-08	2001-09-11	Advanced Medicine, Inc.	Multibinding inhibitors of microsomal triglyceride transferase protein
AU761018B2 (en)	1998-10-08	2003-05-29	Smithkline Beecham Plc	Tetrahydrobenzazepine derivatives useful as modulators of dopamine D3 receptors (antipsychotic agents)
GB9826412D0 (en)	1998-12-03	1999-01-27	Glaxo Group Ltd	Chemical compounds
EP1354604A1 (fr) *	1998-12-23	2003-10-22	G.D. Searle LLC.	Combinaisons pour indications cardiovasculaires
AU776620B2 (en) *	1998-12-23	2004-09-16	G.D. Searle Llc	Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications
ATE242007T1 (de)	1998-12-23	2003-06-15	Searle Llc	Kombinationen von cholesteryl ester transfer protein inhibitoren und nicotinsäure derivaten für kardiovaskuläre indikationen
DE19929065A1 (de) *	1999-06-25	2000-12-28	Bayer Ag	Kombination von MTP-Inhibitoren und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln
DE19929031A1 (de) *	1999-06-25	2000-12-28	Bayer Ag	Kombination von MTP-Inhibitoren und Lipidsenkern und ihre Verwendung in Arzneimitteln
DE19929012A1 (de) *	1999-06-25	2000-12-28	Bayer Ag	Kombination von MTP-Inhibitoren und stoffwechselbeeinflussenden Wirkstoffen und ihre Verwendung in Arzneimitteln
AU6824700A (en) *	1999-07-20	2001-02-05	Novartis Ag	Organic compounds
IL139450A0 (en) *	1999-11-10	2001-11-25	Pfizer Prod Inc	Methods of administering apo b-secretion/mtp inhibitors
CA2324800A1 (fr) *	1999-11-10	2001-05-10	Mary Anne Hickman	Utilisation d'inhibiteurs de secretion d'apo b et/ou de mtp
IL139449A0 (en) *	1999-11-10	2001-11-25	Pfizer Prod Inc	Use of apo b secretion/mtp inhibitors
CA2324801A1 (fr) *	1999-11-10	2001-05-10	Andrew Gordon Swick	Utilisation d'inhibiteurs de secretion d'apo b et/ou de mtp et d'agents contre l'obesite
EP1259484B1 (fr) *	2000-01-18	2005-05-18	Novartis AG	Carboxamides utilises comme inhibiteurs de proteine de transfert triglyceridique microsomique et de la secretion d'apolipoproteine b
CN100393703C (zh) *	2000-03-14	2008-06-11	埃科特莱茵药品有限公司	1,2,3,4-四氢异喹啉的衍生物
AU2001262185A1 (en) *	2000-04-10	2001-10-23	Novartis Ag	Substituted (hetero)aryl carboxamide derivatives as microsomal triglyceride transfer protein (mtp) and apolipoprotein b (apo b) secretion
GB0013383D0 (en) *	2000-06-01	2000-07-26	Glaxo Group Ltd	Therapeutic benzamide derivatives
GB0013346D0 (en) *	2000-06-01	2000-07-26	Glaxo Group Ltd	Therapeutic benzamide derivatives
WO2002014277A1 (fr) *	2000-08-10	2002-02-21	Tanabe Seiyaku Co., Ltd.	Composes de biphenylcarboxamidoisoindoline, procedes de preparation de ceux-ci et produits intermediaires destines a la synthese de ceux-ci
WO2002014276A1 (fr) *	2000-08-10	2002-02-21	Tanabe Seiyaku Co., Ltd.	Composes a base de benzoylaminoisoindoline, leurs procedes de preparation et produits intermediaires utilises dans leur synthese
WO2002020009A1 (fr) *	2000-09-01	2002-03-14	Sankyo Company, Limited	Compositions medicales
JO2654B1 (en)	2000-09-04	2012-06-17	شركة جانسين فارماسوتيكا ان. في	Multiple aryl caroxa amides are useful as lipid - lowering agents
CN1478077A (zh) *	2000-10-05	2004-02-25	��ҩƷ��ҵ��ʽ��	作为apo b分泌抑制剂的苯甲酰胺化合物
JO2409B1 (en)	2000-11-21	2007-06-17	شركة جانسين فارماسوتيكا ان. في	Second-phenyl carboxy amides are useful as lipid-lowering agents
US20040157866A1 (en) *	2001-04-30	2004-08-12	Hisashi Takasugi	Amide compounds
WO2003000235A1 (fr) *	2001-06-22	2003-01-03	Pfizer Products Inc.	Compositions pharmaceutiques de dispersions de medicaments et de polymeres neutres
RS50712B (sr) *	2001-06-28	2010-06-30	Pfizer Products Inc.	Triamid-supstituisani indoli, benzofurani i benzotiofeni kao inhibitori mikrozomalnog triglicerid transfer proteina (mtp) i/ili sekrecije apolipoproteina b (apo b)
US20030144350A1 (en) *	2001-07-20	2003-07-31	Adipogenix, Inc.	Fat accumulation-modulation compounds
WO2003013516A1 (fr) *	2001-08-10	2003-02-20	Adipogenix, Inc.	Composes servant a moduler l'accumulation des graisses
JP2005510564A (ja) *	2001-11-28	2005-04-21	藤沢薬品工業株式会社	アポリポタンパク質ｂ阻害剤としての複素環式アミド化合物
CA2471639A1 (fr)	2002-01-17	2003-07-31	Pharmacia Corporation	Nouveaux composes d'alkyl/aryl hydroxy ou cetothiepine servant d'inhibiteurs du transport des acides biliaires de type ileal et de l'absorption de taurocholate
WO2003063822A2 (fr)	2002-02-01	2003-08-07	Pfizer Products Inc.	Procede de fabrication de dispersions medicamenteuses amorphes solides homogenes sechees par pulverisation au moyen d'un appareil de sechage par pulverisation modifie
RU2293721C2 (ru) *	2002-02-28	2007-02-20	Джапан Тобакко Инк.	Сложноэфирные соединения и их применение в медицине
US7241774B2 (en) *	2002-03-13	2007-07-10	University Of Tennessee Research Foundation	Substituted tetrahydroisoquinoline compounds, methods of making, and their use
WO2004039795A2 (fr) *	2002-10-29	2004-05-13	Fujisawa Pharmaceutical Co., Ltd.	Composes amide
CA2505604A1 (fr) *	2002-12-20	2004-07-08	Pfizer Products Inc.	Inhibiteurs de proteine microsomale de transfert de triglyceride
AU2003286347A1 (en) *	2002-12-20	2004-07-14	Pfizer Products Inc.	Microsomal triglyceride transfer protein inhibitors
KR20050110017A (ko)	2003-03-17	2005-11-22	니뽄 다바코 산교 가부시키가이샤	Ｓ-'２-(''１-(２-에틸부틸)시클로헥실!카르보닐!아미노)페닐!-２-메틸프로판티오에이트의 경구 생체이용율을증가시키는 방법
WO2005021486A1 (fr)	2003-08-29	2005-03-10	Japan Tobacco Inc.	Derive d'ester et utilisation medicale de celui-ci
BRPI0508263B8 (pt)	2004-03-01	2021-05-25	Idorsia Pharmaceuticals Ltd	derivados de 1, 2, 3, 4-tetra-hidro-isoquinolina, composição farmacêutica, e, uso de derivado de 1, 2, 3, 4-tetra-hidro-isoquinolina
DK1725234T4 (en)	2004-03-05	2016-05-09	Univ Pennsylvania	METHODS OF TREATING DISEASES OR DISEASES CONNECTED WITH HYPERLIPIDEMIA AND HYPERCOLESTEROLYMIA WITH MINIMIZATION OF SIDE EFFECTS
US7262318B2 (en) *	2004-03-10	2007-08-28	Pfizer, Inc.	Substituted heteroaryl- and phenylsulfamoyl compounds
US20050288340A1 (en) *	2004-06-29	2005-12-29	Pfizer Inc	Substituted heteroaryl- and phenylsulfamoyl compounds
US20060030623A1 (en) *	2004-07-16	2006-02-09	Noboru Furukawa	Agent for the treatment or prevention of diabetes, obesity or arteriosclerosis
US8101774B2 (en)	2004-10-18	2012-01-24	Japan Tobacco Inc.	Ester derivatives and medicinal use thereof
BRPI0516772A (pt) *	2004-10-25	2008-09-23	Japan Tobacco Inc	formulação sólida com solubilidade e estabilidade melhoradas e método para produção da referida formulação
EP1843819A2 (fr) *	2004-11-15	2007-10-17	Obe Therapy Biotechnology S.A.S.	Procedes de reduction de la graisse corporelle
ATE439347T1 (de)	2004-11-23	2009-08-15	Warner Lambert Co	7-(2h-pyrazol-3-yl)-3,5-dihydroxy-heptansäure- derivate als hmg-co-a-reductase-inhibitoren zur behandlung von lipidemia
JP2006249022A (ja)	2005-03-11	2006-09-21	Sumitomo Chemical Co Ltd	４−（２−メチルフェニル）ベンゾトリフルオライドの製造方法
US8980915B2 (en)	2005-04-19	2015-03-17	Surface Logix, Inc.	Inhibitors of microsomal triglyceride transfer protein and apo-B secretion
CA2609783A1 (fr) *	2005-05-27	2006-12-07	Pfizer Products Inc.	Polytherapie pour le traitement de l'obesite ou le maintien du poids apres une perte ponderale
US7741317B2 (en)	2005-10-21	2010-06-22	Bristol-Myers Squibb Company	LXR modulators
US7888376B2 (en)	2005-11-23	2011-02-15	Bristol-Myers Squibb Company	Heterocyclic CETP inhibitors
US7795262B2 (en) *	2006-03-10	2010-09-14	Neurogen Corporation	Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues
US8383660B2 (en)	2006-03-10	2013-02-26	Pfizer Inc.	Dibenzyl amine compounds and derivatives
US7919506B2 (en)	2006-03-10	2011-04-05	Pfizer Inc.	Dibenzyl amine compounds and derivatives
ES2569558T3 (es) *	2006-04-03	2016-05-11	Roche Innovation Center Copenhagen A/S	Composición farmacéutica que comprende oligonucleótidos antisentido anti-ARNmi
MX2008012219A (es)	2006-04-03	2008-10-02	Santaris Pharma As	Composicion farmaceutica que comprende oligonucleotidos antisentido anti-miarn.
US20090042835A1 (en) *	2006-06-02	2009-02-12	Davis Roger A	Compositions and methods for ameliorating hyperlipidemia
US20080241869A1 (en) *	2006-06-02	2008-10-02	San Diego State University Research Foundation	Compositions and methods for ameliorating hyperlipidemia
CA2666191C (fr) *	2006-10-09	2017-07-11	Santaris Pharma A/S	Composes antagonistes de l'arn pour la modulation de pcsk9
US20100210633A1 (en) *	2006-10-12	2010-08-19	Epix Delaware, Inc.	Carboxamide compounds and their use
WO2008049808A1 (fr)	2006-10-24	2008-05-02	Janssen Pharmaceutica Nv	Dérivés acide tétrahydro-naphtalène-1-carboxylique inhibant le mtp
JO2653B1 (en)	2006-10-24	2012-06-17	شركة جانسين فارماسوتيكا ان. في	Tetrahydroflavin 1-carboxylic acid substituted with pyridine or pyrazine inhibit MTB
EP2094643B1 (fr)	2006-12-01	2012-02-29	Bristol-Myers Squibb Company	Inhibiteurs d'amino cetp étendus
WO2008075949A1 (fr) *	2006-12-20	2008-06-26	Friesland Brands B.V.	Modulation de l'expression génique d'une protéine microsomale de transfert des triglycérides (mtp ou mttp) au moyen de microorganismes alimentaires ingérés/de qualité alimentaire
AU2007338625A1 (en) *	2006-12-21	2008-07-03	Aegerion Pharmaceuticals, Inc.	Methods for treating obesity with a combination comprising a MTP inhibitor and a cholesterol absorption inhibitor
US8470791B2 (en) *	2007-03-22	2013-06-25	Santaris Pharma A/S	RNA antagonist compounds for the inhibition of Apo-B100 expression
WO2008113832A2 (fr) *	2007-03-22	2008-09-25	Santaris Pharma A/S	Composés arn antagonistes courts pour la modulation de l'arnm cible
US20110002855A1 (en) *	2007-06-25	2011-01-06	Neurogen Corporation	Piperazinyl oxoalkyl tetrahydro-beta-carbolines and related analogues
EP2198024A2 (fr) *	2007-08-30	2010-06-23	Santaris Pharma A/S	Composes antagonistes d'arn permettant la modulation de fabp4/ap2
AU2008306327B2 (en) *	2007-10-04	2014-05-15	Roche Innovation Center Copenhagen A/S	Micromirs
HRP20160569T1 (hr)	2007-12-03	2016-07-29	Obe Therapy Biotechnology	Boropeptidni inhibitori enteropeptidaze i njihove uporabe u liječenju pretilosti, pretjerane tjelesne težine i/ili bolesti povezane s abnormalnim metabolizmom masti
US8569282B2 (en)	2007-12-11	2013-10-29	Cytopathfinder, Inc.	Carboxamide compounds and their use
US20090197947A1 (en) *	2008-02-01	2009-08-06	The Research Foundation Of State University Of New York	Medicaments and methods for lowering plasma lipid levels and screening drugs
US8404659B2 (en) *	2008-03-07	2013-03-26	Santaris Pharma A/S	Pharmaceutical compositions for treatment of MicroRNA related diseases
ES2541442T3 (es)	2008-08-01	2015-07-20	Roche Innovation Center Copenhagen A/S	Modulación mediada por microARN de factores estimulantes de colonias
WO2010122538A1 (fr) *	2009-04-24	2010-10-28	Santaris Pharma A/S	Compositions pharmaceutiques pour le traitement de patients souffrant du vhc ne réagissant pas aux interférons
EP2456870A1 (fr)	2009-07-21	2012-05-30	Santaris Pharma A/S	Oligomères anti-sens ciblant pcsk9
EP2986599A1 (fr)	2013-04-17	2016-02-24	Pfizer Inc.	Dérivés de n-pipéridin-3-ylbenzamide dans le traitement des maladies cardiovasculaires
MX391977B (es)	2013-06-27	2025-03-21	Roche Innovation Ct Copenhagen As	Oligómeros antisentido y conjugados con diana en la proteína-convertasa subtilisina/kexina tipo 9(pcsk9).
WO2015065595A1 (fr)	2013-10-30	2015-05-07	Trustees Of Dartmouth College	Procédé d'inhibition sélective d'acat1 dans le traitement de l'obésité, du syndrome métabolique et de l'athérosclérose
WO2016055901A1 (fr)	2014-10-08	2016-04-14	Pfizer Inc.	Composés d'amide substitué
CA2965336A1 (fr) *	2014-10-22	2016-04-28	The Board Of Regents Of The University Of Texas System	Inhibiteurs a petites molecules ciblant le recepteur du domaine discoidine 1 et ses utilisations
CR20210441A (es)	2019-01-18	2022-03-11	Astrazeneca Ab	Inhibidores de la pcsk9 y métodos de uso de los mismos
EP4188372A1 (fr)	2020-07-29	2023-06-07	Amryt Pharmaceuticals Inc.	Lomitapide destiné à être utilisé dans des méthodes de traitement de l'hyperlipidémie et de l'hypercholestérolémie chez des patients pédiatriques
CN113292493A (zh) *	2021-06-23	2021-08-24	上海立科化学科技有限公司	5,7-二氯-1,2,3,4-四氢异喹啉的制备方法
WO2024216197A2 (fr) *	2023-04-13	2024-10-17	Acelot, Inc.	Composés et méthodes de traitement de maladies à agrégation de protéines
US12453728B1 (en)	2024-08-08	2025-10-28	Redux Therapeutics, Llc	Compositions comprising inhibitors of microsomal triglyceride transfer protein and Apo-B secretion

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4022900A (en) *	1970-09-09	1977-05-10	Marion Laboratories, Inc.	Compositions containing 1,2,3,4-tetrahydroisoquinolines used as hypotensive agents
US5595872A (en) *	1992-03-06	1997-01-21	Bristol-Myers Squibb Company	Nucleic acids encoding microsomal trigyceride transfer protein
US5739135A (en) *	1993-09-03	1998-04-14	Bristol-Myers Squibb Company	Inhibitors of microsomal triglyceride transfer protein and method
WO1996040640A1 (fr)	1995-06-07	1996-12-19	Pfizer Inc.	DERIVES DE BIPHENYL-2-ACIDE CARBOXYLIQUE-TETRAHYDRO-ISOQUINOLEINE-6-YL AMIDES, PREPARATION DE CES AMIDES ET UTILISATION EN TANT QU'INHIBITEURS DE LA PROTEINE DE TRANSFERT DE TRIGLYCERIDE MICROSOMAL ET/OU DE LA SECRETION D'APOLIPOPROTEINES B (Apo B)

1997
- 1997-11-03 EP EP97945048A patent/EP0944602A1/fr not_active Withdrawn
- 1997-11-03 JP JP52446498A patent/JP3270764B2/ja not_active Expired - Fee Related
- 1997-11-03 SK SK654-99A patent/SK65499A3/sk unknown
- 1997-11-03 NZ NZ335162A patent/NZ335162A/xx unknown
- 1997-11-03 KR KR1019997004662A patent/KR100334567B1/ko not_active Expired - Fee Related
- 1997-11-03 AU AU46347/97A patent/AU716151B2/en not_active Ceased
- 1997-11-03 EA EA199900416A patent/EA001539B1/ru not_active IP Right Cessation
- 1997-11-03 CA CA002272719A patent/CA2272719C/fr not_active Expired - Fee Related
- 1997-11-03 BR BR9714364A patent/BR9714364A/pt not_active Application Discontinuation
- 1997-11-03 US US09/284,466 patent/US6121283A/en not_active Expired - Fee Related
- 1997-11-03 YU YU23499A patent/YU23499A/sh unknown
- 1997-11-03 TR TR1999/01180T patent/TR199901180T2/xx unknown
- 1997-11-03 IL IL12974497A patent/IL129744A0/xx unknown
- 1997-11-03 CN CN97180033A patent/CN1238764A/zh active Pending
- 1997-11-03 WO PCT/IB1997/001368 patent/WO1998023593A1/fr not_active Ceased
- 1997-11-04 HN HN1997000144A patent/HN1997000144A/es unknown
- 1997-11-05 TW TW086116476A patent/TW502023B/zh not_active IP Right Cessation
- 1997-11-14 PA PA84416A patent/PA8441601A1/es unknown
- 1997-11-20 AP APAP/P/1997/001145A patent/AP804A/en active
- 1997-11-24 PE PE1997001062A patent/PE17199A1/es not_active Application Discontinuation
- 1997-11-25 ID IDP973763A patent/ID18995A/id unknown
- 1997-11-25 GT GT199700122A patent/GT199700122A/es unknown
- 1997-11-25 UY UY24789A patent/UY24789A1/es not_active Application Discontinuation
- 1997-11-26 TN TNTNSN97193A patent/TNSN97193A1/fr unknown
- 1997-11-26 MA MA24877A patent/MA26451A1/fr unknown
- 1997-11-26 HR HR60/032,307A patent/HRP970642A2/hr not_active Application Discontinuation
- 1997-11-26 ZA ZA9710641A patent/ZA9710641B/xx unknown
- 1997-11-26 DZ DZ970208A patent/DZ2358A1/fr active
- 1997-11-26 AR ARP970105560A patent/AR010309A1/es unknown
1999
- 1999-04-30 IS IS5040A patent/IS5040A/is unknown
- 1999-05-19 OA OA9900106A patent/OA11050A/en unknown
- 1999-05-26 BG BG103434A patent/BG103434A/xx unknown
- 1999-05-26 NO NO19992525A patent/NO312760B1/no unknown
- 1999-05-26 BG BG108830A patent/BG108830A/bg unknown
2002
- 2002-02-19 CN CN02105189A patent/CN1380289A/zh active Pending
- 2002-09-17 CZ CZ20023137A patent/CZ292160B6/cs not_active IP Right Cessation

Also Published As

Publication number	Publication date
DZ2358A1 (fr)	2002-12-28
HN1997000144A (es)	1997-12-16
EP0944602A1 (fr)	1999-09-29
AR010309A1 (es)	2000-06-07
EA199900416A1 (ru)	1999-12-29
CN1238764A (zh)	1999-12-15
US6121283A (en)	2000-09-19
NZ335162A (en)	2000-01-28
MA26451A1 (fr)	2004-12-20
NO312760B1 (no)	2002-07-01
ZA9710641B (en)	1999-05-26
CN1380289A (zh)	2002-11-20
TNSN97193A1 (fr)	2005-03-15
WO1998023593A1 (fr)	1998-06-04
GT199700122A (es)	1999-05-19
ID18995A (id)	1998-05-28
OA11050A (en)	2002-03-07
SK65499A3 (en)	2001-05-10
NO992525D0 (no)	1999-05-26
TR199901180T2 (xx)	1999-08-23
CA2272719C (fr)	2002-10-01
AU716151B2 (en)	2000-02-17
JP2000505810A (ja)	2000-05-16
TW502023B (en)	2002-09-11
PE17199A1 (es)	1999-02-19
NO992525L (no)	1999-05-26
AP804A (en)	2000-01-28
BR9714364A (pt)	2000-03-21
BG103434A (en)	2000-07-31
HRP970642A2 (en)	1998-10-31
JP3270764B2 (ja)	2002-04-02
AU4634797A (en)	1998-06-22
IS5040A (is)	1999-04-30
EA001539B1 (ru)	2001-04-23
IL129744A0 (en)	2000-02-29
UY24789A1 (es)	2000-09-29
KR20000057269A (ko)	2000-09-15
PA8441601A1 (es)	2000-05-24
YU23499A (sh)	2001-07-10
BG108830A (bg)	2005-10-31
KR100334567B1 (ko)	2002-05-03
CZ292160B6 (cs)	2003-08-13
AP9701145A0 (en)	1998-01-31

Publication	Publication Date	Title
CA2272719A1 (fr)	1998-06-04	Amides inhibant la secretion d'apo b et/ou la proteine mtp
CA2356158A1 (fr)	2000-07-06	Combinaisons d'inhibiteurs de la proteine de transfert du cholesteryle-ester et de derives de l'acide nicotinique utilisees dans le cadre de troubles cardio-vasculaires
EP1090908A3 (fr)	2001-05-16	Derives de cyclobutane utilisés comme inhibiteurs de la protéine farnesyltransferase
AU7756694A (en)	1995-05-18	Substituted heterocyclic carboxamide esters, their preparation and their use as pharmaceuticals
NZ235323A (en)	1993-02-25	Amide derivatives and pharmaceutical compositions thereof
IL111454A0 (en)	1994-12-29	Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals
PT84975A (en)	1987-06-01	Trans-6-]2-(3-or 4-carboxamido-substituted pyrrol-1-yl) alkyl)-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
IL148014A0 (en)	2002-09-12	Cell adhesion inhibitors
IL143949A0 (en)	2002-04-21	Combinations of cholesteryl ester transfer protein inhibitors and fibric acid derivatives for cardiovascular indications
CA2145407A1 (fr)	1994-04-14	Nouveaux reactifs pour combinaisons peptidiques
WO2001000577A3 (fr)	2002-01-24	Preparation de piperidine-4-ones substituees
CA2347853A1 (fr)	2000-05-18	Processus de racemisation de [2-(2-thyenyl)ethylamino](2-halogenophenyl)acetamides
HU9603451D0 (en)	1997-02-28	Lactam inhibitors of cholesterol esterase
CO4650034A1 (es)	1998-09-03	Amidas inhibidoras de la secrecion de apo b/mtp
ECSP972325A (es)	1998-12-14	Amidas inhibidoras de la secrecion de apo b/mtp
WO2002053537A8 (fr)	2002-08-08	Procede de preparation de (?)-trans-4-p-fluorophenyl-3-hydroxymethyl-1-methylpiperidine
AU4429097A (en)	1998-04-02	Process for the preparation of ferric chelate solutions of alkali metal polyamino succinic acids
ZA985179B (en)	1999-01-08	Process for producing medicaments which comprise HMG CoA reductase inhibitors
HK1005776A1 (en)	1999-01-22	Isoquinolines
AU2407400A (en)	2000-07-24	Process for the formation of intermediates useful for the preparation of pharmaceuticals
MX9708077A (es)	1998-01-31	Derivados de ciclobutano como inhibidores de sintasa de escualeno y farnesiltransferasa de proteina.
HUP9600941A2 (en)	1997-06-30	Process for the preparation of 1-cyclopropyl-6-fluoro-1,4-dihydro-7-[1s,4s]-5-methyl-2,5-diazabicyclo-[2.2.1]hept-2-yl-4-oxo-3-quinolinecarboxylic acid and its salts
HK1030596A (en)	2001-05-11	Process for the preparation of ferric chelate solutions of alkali metal polyamino succinic acids

Legal Events

Date	Code	Title	Description
1999-05-26	EEER	Examination request
2007-11-05	MKLA	Lapsed